Skip to main content

Table 2 Patient characteristics at baseline

From: Validation of the Fatigue Severity Scale in chronic hepatitis C

  Treatment-naïve (PILLAR) Treatment-experienced (ASPIRE)
  All patients (ITT) Patients with baseline FSS and ≥1 follow-up All patients (ITT) Patients with baseline FSS and ≥1 follow-up
N = 386 N = 241 N = 462 N = 446
Sex, n (%) N = 386 N = 241 N = 462 N = 446
 Male 213 (55.2) 136 (56.4) 311 (67.3) 301 (67.5)
 Female 173 (44.8) 105 (43.6) 151 (32.7) 145 (32.5)
Age, mean, SD (years) 44.0 (11.81) 45.9 (10.37) 48.9 (10.36) 48.9 (10.37)
Race, n (%) N = 386 N = 241 N = 462 N = 446
 Caucasian 362 (93.8) 225 (93.4) 428 (92.6) 414 (92.8)
 Non-Caucasian 24 (6.2) 16 (6.6) 34 (7.4) 32 (7.2)
Region, n (%) N = 386 N = 241 N = 462 N = 446
 North America 82 (21.2) 52 (21.6) 120 (26.0) 113 (25.3)
 Latin America 0 0 0 0
 Europe/Israel 262 (67.9) 147 (61.0) 313 (67.7) 306 (68.6)
 Asia 42 (10.9) 42 (17.4) 29 (6.3) 27 (6.1)
HCV RNA, mean (log10 IU/mL) 6.5 (0.61) 6.5 (0.64) 6.5 (0.57) 6.5 (0.56)
Genotype, n (%) N = 383 N = 239 N = 455 N = 439
 1a 173 (45.2) 122 (51.0) 188 (41.3) 178 (40.5)
 1b 208 (54.3) 115 (48.1) 262 (57.6) 257 (58.5)
 Other 2 (0.5) 2 (0.8) 5 (1.1) 4 (0.9)
METAVIR score, n (%) N = 386 N = 241 N = 455 N = 439
 F0–F2 332 (86.0) 203 (84.2) 286 (62.9) 278 (63.3)
 F3 53 (13.7) 38 (15.8) 86 (18.9) 83 (18.9)
 F4 1 (0.3) 0 83 (18.2) 78 (17.8)
Baseline PRO (mean)    
 FSS total score 3.3 (1.58) 3.3 (1.57) 3.3 (1.65) 3.3 (1.65)
 EQ-5D VAS 82.4 (15.28) 81.8 (15.75) 80.4 (16.47) 80.4 (16.42)
  1. EQ-5D VAS European Quality of Life 5 dimension questionnaire visual analog scale, FSS Fatigue Severity Scale, HCV hepatitis C virus, ITT intent to treat, PRO patient-reported outcome, SD standard deviation.